Viking Therapeutics Faces Investor Scrutiny Following Mixed Obesity Drug Results

Viking Therapeutics shares encountered selling pressure as the market digested Phase II trial data for its oral obesity treatment candidate VK2735. While the study demonstrated impressive efficacy in weight reduction, investor confidence was shaken by notably high discontinuation rates linked to adverse side effects.

The trial revealed a significant dose-dependent response. Patients receiving the highest dosage of the oral GLP-1 drug achieved an average weight loss of 12.2% over a 13-week treatment period. However, this promising efficacy came with a substantial drawback: a high incidence of gastrointestinal side effects that led many participants to withdraw from the study.

Key findings from the clinical trial include:
* Top dosage cohort achieved 12.2% mean weight reduction in 13 weeks
* Elevated discontinuation rates primarily due to gastrointestinal complications
* Lower dosage groups demonstrated improved tolerability while maintaining strong efficacy

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

This mixed outcome suggests Viking must carefully optimize the balance between the drug’s potency and its patient tolerability. The negative market sentiment is reflected in the stock’s current downward trend, with technical indicators pointing to a bearish near-term outlook.

Beyond the oral formulation, Viking’s pipeline presents additional opportunities. The subcutaneous injectable version of VK2735 has already reported positive Phase II results and is preparing to advance into Phase III trials. Success in these later-stage studies could significantly bolster the company’s market position.

Furthermore, Viking is developing another promising candidate, VK2809, targeting metabolic dysfunction-associated steatohepatitis (MASH). This program is also approaching late-stage clinical trials, potentially providing another catalyst for the stock in the coming months.